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Programmed cell death 4ABSTRACT
Objective: To study the inhibition effect of miR-106a inhibitor on tumor growth of
ovarian cancer xenografts mice.
Methods: BALB/c mice were selected as experimental animals, ovarian cancer SKOV-3
cells transfected with miR-106a inhibitor and its negative control were inoculated sub-
cutaneously, intratumoral injection of miR-106a inhibitor and its negative control were
continued after tumor formation, and they were enrolled as treatment group and model
group, respectively. Tumor volume and weight as well as Ki-67 and programmed cell
death 4 (PDCD4) expression were determined; miR-106a inhibitor and its negative
control as well as miR-106a mimic and its negative control were transfected into SKOV-3
cells, and expression of PDCD4 in cells was determined.
Results: Tumor tissue volume and weight as well as mRNA expression and protein
expression of Ki-67 in treatment group were signiﬁcantly lower than those in the model
group while mRNA expression and protein expression of PDCD4 were signiﬁcantly
higher than those in the model group; transfection of miR-106a mimic could decrease
mRNA expression and protein expression of PDCD4 in SKOV-3 cells, and transfection
of miR-106a inhibitor could increase mRNA expression and protein expression of
PDCD4 in SKOV-3 cells.
Conclusions: Transfection of miR-106a inhibitor can inhibit the growth of tumor in
ovarian cancer xenografts mice through increasing the expression of PDCD4.1. Introduction
Ovarian cancer is one of the common malignant tumors of
female reproductive system, and the death caused by ovarian
cancer ranks ﬁrst in gynecologic malignant tumors. Ovarian
cancer patients can obtain complete remission after cytoreduc-
tive surgery and adjuvant chemotherapy, but the overall prog-
nosis is still poor, and there will be local recurrence and distant
metastasis in vast majority of patients [1,2]. Ovarian cancer
involves many links, genes and steps, and the inactivation of
tumor suppressor genes and activation of proto-oncogene aswell as abnormal expression of apoptosis-related genes and
invasion-related genes can all cause tumor recurrence and
metastasis [3,4]. However, the upstream signals regulating the
expression of above malignant tumor-related genes are still not
clariﬁed at present, and accurate targets for the clinical treatment
of ovarian cancer are also scarce. MicroRNA (miRNA) is a
family of evolutionarily highly conserved non-coding small
molecule RNA found in recent years, which is combined with
target gene mRNA 30 untranslated region (30UTR) so as to
regulate the expression of multiple genes [5,6]. Studies have
conﬁrmed that miR-106a has the characteristics of proto-
oncogene, and participates in the occurrence and development
of lung cancer [7], gastric cancer [8], colon cancer [9] and many
other kinds of malignant tumors, thus it was speculated in the
study whether miR-106a was also involved in the occurrence
and development of ovarian cancer, and whether inhibiting the
biological functions of miR-106a could inhibit the growth of
ovarian cancer. In the following study, transfection of miR-106a
inhibitor was adopted to inhibit the biological effect of miR-106rticle under the CC BY-NC-ND license (http://
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xenografts mice was analyzed.
2. Materials and methods
2.1. Experimental materials
Human ovarian cancer SKOV3 cell lines were bought from
the cell center of Union Medical College, RPMI1640 medium
and fetal bovine serum were purchased from Gibco Company,
miR-106a mimic and negative control as well as miR-106a in-
hibitor and negative control were synthesized by Genepharma
Company (Shanghai), and Lipofectamine2000 transfection re-
agents were purchase from Invitrogen Company (USA). RNA
extraction kits, reverse transcription kits and ﬂuorescence
quantitative PCR kits were bought from Tiangen Biotech
Company (Beijing), and Elisa kits were purchased from West-
ang Biotech Company (Shanghai).
Twenty SPF female BALB/c mice with body mass (18–24) g
were bought and raised by the animal center of Hebei Univer-
sity, they were raised under constant temperature (18–22) C
and constant humidity 50%–80%, and they had free water and
feeding. Mice were randomly divided into model group and
treatment group, 10 in each group. The animal experiment was
approved by the ethics committee of Afﬁliated Hospital of Hebei
University.
2.2. Experimental methods
2.2.1. Cell culturing and transfection of miR-106a
inhibitor
SKOV3 cell lines were recovered and then cultured in
RPMI1640 medium containing 10% fetal bovine serum, cells
were digested and sub-cultured with 0.25% trypsin after growing
all over, then they were respectively inoculated in culture bottle
and Petri dishes, cells in the culture bottles were used for contin-
uous digestion and passage, cells in the Petri dishes were used for
processing, and the methods were as follows: miR-106a inhibitor,
miR-106a mimic, NC inhibitor and NC mimic powder was
conﬁgured to 20 mmol/L solution, and the proportion of 6 mL
Lipofectamine2000 and 3 mL miR inhibitors or mimics per 1 mL
medium was followed for transfection for consecutive 24 h.
2.2.2. Establishment and intervention methods of
xenografts mice
SKOV-3 cells transfected with miR-106a inhibitors or NC
inhibitors were taken and digested to get cell suspension, the cell
density was adjusted to 107/mL, model group received subcu-
taneous injection of 0.5 mL SKOV-3 cell suspension transfected
with NC inhibitor into the right upper extremity axillary lateral
side, treatment group received subcutaneous injection of 0.5 mL
SKOV-3 cell suspension transfected with miR-106a inhibitor
into the right upper extremity axillary lateral side, and after 7 d,
those with tumor size more than 3 mm3 were successfully
established xenografts models and then received the following
intervention: on the 7th day after local injection of SKOV-3 cell
suspension, model group received intratumoral injection of 5 mL
NC inhibitor + 5 mL Lipofectamine2000 mixture, treatment
group received intratumoral injection of 5 mL miR-106a
inhibitor + 5 mL Lipofectamine2000 mixture, once every four
days, for a total of 10 times.2.2.3. Assessment of tumor growth
On the 7th day after local injection of SKOV-3 cell sus-
pension as well as the 10th day, 20th day, 30th day and 40th day
after local injection of miR-106a inhibitor, vernier caliper was
used to measure the maximum major diameter (a) and the
maximum transverse diameter (b) of tumor, the maximum
transverse diameter referred to the maximum length of the line
perpendicular to the maximum major diameter, and tumor tissue
volume V = 0.5 × a × b2. On the 40th day after local injection of
miR-106a inhibitor or NC inhibitor, the volume of tumor tissue
was measured, and then the mice were executed and anatomized
to obtain and weigh tumor tissue.
2.2.4. Fluorescence quantitative PCR detection methods
Extraction of RNA in cells was by total RNA extraction kit
for cells, extraction of RNA in tumor tissue was by total RNA
extraction kit for animal tissue, RNA was obtained and then
reverse-transcribed into cDNA by reverse transcription Kit
TIANScript II RT Kit, then ﬂuorescence quantitative PCR Kit
was used to amplify Ki-67 and programmed cell death 4
(PDCD4) genes as well as b-actin, and ampliﬁcation conditions
were as follows: 95 C initial denaturation 5 min, 95 C 30 s,
speciﬁc annealing temperature 30 s, 72 C 30 s and repeating for
40 cycles, and after ampliﬁcation curve was obtained, 2−DDCt
formula was followed to calculate the relative mRNA levels of
Ki-67 and PDCD4.
2.2.5. Elisa detection methods
Treated SKOV3 cells were collected, added in protein lysis
buffer, fully broken and centrifuged to get protein suspension;
tumor tissue was collected, added in PBS, fully grinded and
centrifuged to get protein suspension. Elisa kits for PDCD4 and
Ki-67 were used to determine protein content.
2.2.6. Statistical methods
SPSS20.0 software was used to input and analyze data,
measurement data comparison between two groups was by t test
and P < 0.05 indicated statistical signiﬁcance in differences.
3. Results
3.1. Tumor tissue growth
On the 7th day after local injection of SKOV-3 cell sus-
pension (the time of tumor formation), tumor tissue volume in
treatment group was (10.32 ± 1.86) mm3 vs. (34.28 ± 6.61) mm3
and signiﬁcantly lower than that in the model group; on the 10th
day, 20th day, 30th day and 40th day after treatment, tumor
volume of both groups gradually increased, and tumor tissue
volume in treatment group at various points in time were
signiﬁcantly lower than those in the model group; mice were
executed and anatomized to get tumor tissue, and tumor tissue
weight in treatment group was (103.56 ± 17.78) mg vs.
(523.25 ± 79.26) mg and signiﬁcantly lower than that in the
model group, shown in Table 1.
3.2. Ki-67 expression in tumor tissue
Detection of Ki-67 mRNA expression in tumor tissue of
model group and treatment group by ﬂuorescence quantitative
PCR showed that mRNA level of Ki-67 in tumor tissue of
Table 1
Volume and weight of tumor tissue on the 10th day, 20th day, 30th day and 40th day after treatment.
Groups Tumor tissue volume (mm3) Tumor tissue weight (mg)
0 10 20 30 40
Treatment group 10.32 ± 1.86** 33.51 ± 4.61** 49.42 ± 5.18** 65.20 ± 8.62** 82.35 ± 11.64** 103.56 ± 17.78**
Model group 34.28 ± 6.61 94.29 ± 11.34 176.55 ± 24.18 258.24 ± 41.35 379.13 ± 52.48 523.25 ± 79.26
Compared with model group at the same point in time, **P < 0.01.
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signiﬁcantly lower than that of the model group; detection of Ki-
67 protein expression in tumor tissue of model group and
treatment group by Elisa showed that protein level of Ki-67 in
tumor tissue of treatment group was (35.96 ± 6.13) vs.
(127.75 ± 21.45) mg/mg total protein and signiﬁcantly lower
than that of the model group.
3.3. PDCD4 expression in tumor tissue
Detection of PDCD4 mRNA expression in tumor tissue of
model group and treatment group by ﬂuorescence quantitative
PCR showed that mRNA level of PDCD4 in tumor tissue of
treatment group was (2.86 ± 0.61) vs. (1.00 ± 0.19) and
signiﬁcantly higher than that of the model group; detection of
PDCD4 protein expression in tumor tissue of model group and
treatment group by Elisa showed that protein level of PDCD4 in
tumor tissue of treatment group was (186.36 ± 31.56) vs.
(42.84 ± 7.12) mg/mg total protein and signiﬁcantly higher than
that of the model group.
3.4. PDCD4 expression in SKOV-3 cells
After transfection of miR-106a mimic and NC mimic, anal-
ysis of PDCD4 expression in SKOV-3 cells was as follows:
compared with cells transfected with NC mimic, mRNA content
of PDCD4 (0.48 ± 0.08) vs. (1.00 ± 0.11) and protein content of
PDCD4 (15.61 ± 2.32) vs. (34.47 ± 5.28) mg/mg total protein
signiﬁcantly decreased in cells transfected with miR-106a
mimic. After transfection of miR-106a inhibitor and NC inhib-
itor, analysis of PDCD4 expression in SKOV-3 cells was as
follows: compared with cells transfected with NC inhibitor,
mRNA content of PDCD4 (2.52 ± 0.42) vs. (1.00 ± 0.14) and
protein content of PDCD4 (70.25 ± 10.38) vs. (37.23 ± 6.13) mg/
mg total protein signiﬁcantly increased in cells transfected with
miR-106a inhibitor.
4. Discussion
Metastasis, recurrence rate and mortality rate are high in
ovarian cancer patients after cytoreductive surgery and adjuvant
chemotherapy, and the inactivation of tumor suppressor genes
and the activation of proto-oncogene as well as abnormal
expression of apoptosis-related genes and invasion-related genes
are all closely related to the recurrence and metastasis of ovarian
cancer. miRNA is a class of small non-coding RNA with length
of (22–25) bp, and can be combined with target gene mRNA
30UTR region to lead to mRNA degradation or inhibit mRNA
translation [10,11]. In the occurrence and development of
malignant tumor, some fragile area in chromosomes can
change, and more than 50% of the miRNA genes are in thefragile area of chromosomes and with abnormal expression,
resulting in changes in the expression of a variety of
downstream target genes and causing corresponding changes
in cell biological behavior [12,13].
miR-106a is a class of miRNA with proto-oncogene prop-
erties found in recent years, and it shows the trend of high
expression in lung cancer [7], gastric cancer [8], colon cancer [9]
and many other malignant tumor tissues. Experimental cell
research of domestic LI Min and others [14] conﬁrms that
miR-106 is highly expressed in metastatic ovarian cancer cells
SKOV-3 and miR-106a mimic can promote ovarian cancer cell
migration and invasion in vitro. So it was speculated that miR-
106a had promoting effect on the occurrence and development
of ovarian cancer, and antagonizing the biological function of
miR-106a in cells could inhibit the development of ovarian
cancer. But relevant study in vivo on the relationship between
miR-106a and the occurrence and development of ovarian can-
cer is still scarce at present.
In this study, transfection of miR-106a inhibitor was adopted
to antagonize the biological effect of miR-106a in ovarian cancer
cells, and after subcutaneous injection of ovarian cancer cells
transfected with miR-106a inhibitor and NC inhibitor, obser-
vation of the tumor formation showed that at the time of tumor
formation, tumor tissue volume of treatment group was signiﬁ-
cantly less than that of model group. That means that after
subcutaneous injection of ovarian cancer cells transfected with
miR-106a inhibitor into mice, tumor volume is smaller at the
time of tumor formation. In the process of tumor growth,
continuous intratumoral injection of miR-106a inhibitor can
further inhibit tumor growth, and tumor tissue volume of treat-
ment group on the 10th day, 20th day, 30th day and 40th day
after injection were signiﬁcantly less than those of model group
and the weight of tumor tissue from anatomizing executed mice
was signiﬁcantly lower than that of model group. Ki-67 is a
nuclear antigen located in the nucleus and can reﬂect the cell
proliferation activity, and analysis of Ki-67 expression in tumor
tissue in the research conﬁrmed that mRNA expression and
protein expression of Ki-67 in tumor tissue of treatment group
were signiﬁcantly lower than those of the model group. Thus it
further conﬁrms that transfection of miR-106a inhibitor can
inhibit the growth of ovarian cancer, reduce tumor volume and
reduce tumor weight.
The way for miRNA to regulate gene expression is to be
combined with target gene mRNA 30UTR to induce mRNA
degradation and inhibit mRNA translation. Studies have re-
ported that PDCD4 is an important tumor suppressor gene in the
body [15–17] and also a target gene regulated by miR-106a [18].
Protein encoded by PDCD4 contains two highly conserved a-
helical MA-3 domains, can interact with RNA helicase and
eIF4A protein, and can also adjust the phosphorylation status of
a variety of downstream signaling molecules, thus inhibiting cell
proliferation and invasion [19,20]. Research of Wei N [21] shows
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activity is lost in ovarian cancer tissue. In the research,
analysis of PDCD4 expression in tumor tissue conﬁrmed that
after transfection of miR-106a inhibitor, PDCD4 expression in
tumor tissue increased signiﬁcantly. Thus it demonstrates that
miR-106a can adjust the expression of PDCD4 in ovarian cancer
tissue, thereby affecting the growth of tumor. In order to further
deﬁne whether miR-106a directly regulated PDCD4 expression,
miR-106a mimic and inhibitor were transfected into ovarian
cancer cells respectively in the study, and analysis of mRNA and
protein expression of PDCD4 showed that miR-106a mimic
could inhibit PDCD4 expression and the inhibitor could increase
PDCD4 expression. It indicates that miR-106a can target and
regulate PDCD4 expression in ovarian cancer cells.
To sum up, transfection of miR-106a inhibitor can inhibit the
growth of tumor in ovarian cancer xenografts mice through
increasing the expression of PDCD4.
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